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Abstract
Background: An important challenge of the longitudinal analysis of health-related quality of life (HRQOL) is the
potential occurrence of a Response Shift (RS) effect. While the impact of RS effect on the longitudinal analysis of
HRQOL has already been studied, few studies have been conducted on its impact on the determination of the
Minimal Important Difference (MID). This study aims to investigate the impact of the RS effect on the determination
of the MID over time for each scale of both EORTC QLQ-C30 and QLQ-BR23 questionnaires in breast cancer
patients.
Methods: Patients with breast cancer completed the EORTC QLQ-C30 and the EORTC QLQ-BR23 questionnaires at
baseline (time of diagnosis; T0), three months (T1) and six months after surgery (T2). Four hospitals and care centers
participated in this study: cancer centers of Dijon and Nancy, the university hospitals of Reims and Strasbourg At T1
and T2, patients were asked to evaluate their HRQOL change during the last 3 months using the Jaeschke transition
question. They were also asked to assess retrospectively their HRQOL level of three months ago.
The occurrence of the RS effect was explored using the then-test method and its impact on the determination of
the MID by using the Anchor-based method.
Results: Between February 2006 and February 2008, 381 patients were included of mean age 58 years old (SD =
11). For patients who reported a deterioration of their HRQOL level at each follow-up, an increase of RS effect has
been detected between T1 and T2 in 13/15 dimensions of QLQ-C30 questionnaire, and 4/7 dimensions of QLQ-
BR23 questionnaire. In contrast, a decrease of the RS effect was observed in 8/15 dimensions of QLQ-C30
questionnaire and in 5/7 dimensions of QLQ-BR23 questionnaire in case of improvement. At T2, the MID became ≥
5 points when taking into account the RS effect in 10/15 dimensions of QLQ-C30 questionnaire and in 5/7
dimensions of QLQ-BR23 questionnaire.
Conclusions: This study highlights that the RS effect increases over time in case of deterioration and decreases in
case of improvement. Moreover, taking the RS into account produces a reliable and significant MID.
Keywords: Health-related quality of life, Response shift, Minimal important difference, Then-test, Anchor-based
method
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Background
In oncology clinical trials including health-related quality
of life (HRQOL) as an endpoint, the main objective is to
assess the impact of the treatment on patient’s HRQOL
level over time. Consequently, a longitudinal assessment
of HRQOL is desirable. The interpretation of the results
of the longitudinal analysis of such data must be made
in both statistical and clinical point of view in order to
produce meaningful results for both patients and clini-
cians [1, 2]. The minimal important difference (MID)
was defined as the smallest change between two scores
in a treatment outcome that a patient would identify as
important [3–6].
For the European Organization of Research and Treat-
ment of Cancer (EORTC) HRQOL questionnaires, the
MID is generally fixed to 5 or 10 points for each score
standardized on a 0–100 scale [2]. Nevertheless, this
MID must be studied and determined for each HRQOL
questionnaire and according to each cancer site. This
was already made for the EORTC module of lung and
brain cancer as example [7, 8]. To our knowledge, it has
not yet been done for the EORTC QLQ-BR23 module
for breast cancer patients. Furthermore, it is mandatory
to not ignore the importance of this MID and to take it
into account in the interpretation of HRQOL results.
Indeed, the longitudinal analysis of HRQOL remains
complex, particularly due to the potential occurrence of
a response shift (RS) effect characterizing the process of
adaptation of the patient in relation to the illness and its
treatment [9, 10]. Thus, patients may not assess with the
same criteria their HRQOL level over time.
The RS refers to a change in the meaning of HRQOL
over time. Its definition proposed by Sprangers and
Schwartz consists of three components:
– A recalibration: change in the respondent’s internal
standards of measurement;
– A reprioritization: change in the importance of the
component domains that constitute HRQOL;
– A reconceptualization: redefinition of the concept of
HRQOL [9, 10].
Several methodological or statistical methods have
been proposed to characterize the occurrence of the RS
effect, such as the then-test [9] or structural equation
modeling [11]. The then-test consists to ask to patients
post-treatment to provide their current levels (post-test)
but also their pre-test levels in retrospect (then-test). Its
impact on longitudinal HRQOL analysis has also been
studied in breast cancer patients [12]. However, at this
time, few researches have focused on the impact of RS
effect on the determination of the MID [13]. Thus, the
MID recommended for future studies could thus be
under or over estimated by a potential RS effect.
The occurrence of the RS effect could affect the inter-
pretation of change in HRQOL scores. In this case, we
need to assess the occurrence of the RS to obtain a valid
and reliable assessment of change over time. In particu-
lar, when we have longitudinal data to determine the
MID, it is therefore important to take into account this
RS to assess the true change represented by the MID.
Many studies aimed to estimate the MID without
taking into account the occurrence of the RS [3, 4]. To
our knowledge, only one study explored the impact of
the RS on the MID determination. This study demon-
strated that the recalibration component of the RS effect
does not have an important effect in patients with
multiple myeloma who respond to treatment, i.e. for
which a HRQOL improvement was observed. However,
the author showed that RS does have an important effect
in case of deterioration of patient’s HRQOL level [13].
Thus it seems to be essential to study the impact of the
RS effect in studies aiming to determine the MID, and
to study if this RS impact differentially patients who im-
proved to those who deteriorate over time. Only two
measurement times (at inclusion and after three
months) were considered in the study of Kvam et al.
which allow detecting the importance of RS effect on
deteriorating or improving of HRQOL and its direction
after three months [13]. However, since the RS effect is a
longitudinal process, it could be relevant to include
more time points in order to study the longitudinal
change of the RS effect over time.
In this context, the objective of this work was to study
the impact of the recalibration component of the RS
effect on the determination of the MID in breast cancer
patients between three measurement times using the
EORTC QLQ-C30 cancer specific questionnaire and its
breast cancer module QLQ-BR23.
Methods
Patients
Data from a prospective, multicenter, cohort study were
used including all women hospitalized for the diagnosis
or treatment of primary breast cancer or for a suspicion
of breast cancer. Patients who have other primary cancer
sites were excluded. Patients already hospitalized or
treated for breast cancer were not included. Written
informed consent was obtained from all participants.
The protocol was approved by the ethics committees
(“Comité de Protection des Personnes”). The complete




HRQOL was assessed using the EORTC QLQ-C30
cancer-specific questionnaire and its QLQ-BR23 breast
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cancer module. Three measurement times were used: at
baseline (initial examination or initial hospitalization,
T0), three months (T1) and six months later (T2).
The QLQ-C30 consists of 30 items measuring five
functional scales (physical, role, emotional, cognitive and
social functioning), a global health status (GHS), finan-
cial difficulties and eight scales of symptoms (fatigue,
nausea and vomiting, pain, dyspnea, insomnia, appetite
loss, constipation, diarrhea) [15]. One score is generated
per dimension and standardized on a 0 to 100 scale in
order that a high score reflects a high GHS, functional
and symptomatic level [16].
The QLQ-BR23 module is specific to breast cancer. It
includes 23 items allowing to assess four functional
scales (body image, sexual functioning, sexual enjoy-
ment, future perspectives) and four symptom scales (sys-
temic therapy side effects, breast symptoms, arm
symptoms, upset by hair loss) [17]. As for the QLQ-C30,
one score is generated per dimension on a 0–100 scale
in order that a high score represents a high level of func-
tioning and a high symptomatic level.
Questionnaires have been distributed by a clinical re-
search assistant to the patients during the hospitalization
or after a consultation or sending by the post.
Then-test assessment
In this study, the then-test method was used to detect
changes in internal standards, namely the “recalibration”
component of the RS [18].
At each follow-up time point, one prospective and one
retrospective measurement were performed. For the
retrospective measurement (then-test) at T1, patients
were asked to re-evaluate their baseline HRQOL level
(three months before). At T2 (six months), patients were
asked to re-evaluate their HRQOL level at three months
(retrospective assessment of HRQOL level at T1 (three
months)).
Assessment of change in HRQOL level
The anchor-based method was used to determine the
MID according to the Jaeschke transition question [3].
At three (T1) and six months (T2), patients were asked
to evaluate their HRQOL change in the last three
months. The question was asked by the following way:
“During the past three months, do you consider your
HRQOL:
– Did not change globally
– Deteriorated: very much, much, a little
– Improved: a little, much, very much”
Since the Jaeschke transition question was asked to
the patients at T1 and then at T2, patients can deterior-
ate between T0 and T1 and then can improve between
T1 and T2. Thus, patients in the group “little worse” at
T1 can then be in the group “little better” at T2.
To facilitate the interpretation of the results and to
yield sufficient numbers of patients in each category, we
brought the two categories “very much” and “much” in a
single category to get finally five response categories for
the anchor (much better, little better, unchanged, little
worse, and much worse).
Statistical methods
Statistical considerations and missing data
All dimensions of both QLQ-C30 and QLQ-BR23 ques-
tionnaires were analysed except the hair loss dimension
of the QLQ-BR23 due to missing data (few patients con-
cerned at the stage of the beginning of the treatment).
Only patients with available data at each time meas-
urement were included in the analyses.
All tests were performed at the statistical level of 0.05
with no adjustment on multiple tests. All tests were
performed at the statistical level of 0.05 with no adjust-
ment on multiple tests. All p-values were given for infor-
mation only since sample sizes for each test do not allow
to produce some results with a high statistical power.
The analyses and tests were made as an exploratory pur-
pose only, we are more interested about clinical meaning
of the difference instead of statistical significance.
Scores were calculated according to the recommenda-
tions of the EORTC scoring manual [15]: if at least half
of the items per dimension were answered, the score
was estimated on available items, i.e. considering that
missing items were equal to the mean of answered items
(simple imputation by the personal mean).
Missing data profile was already explored in a previous
study [19]. They were considered as missing at random.
Descriptive analysis
Baseline sociodemographics and clinical characteristics
of the patients as well as baseline HRQOL scores were
described using mean and standard deviation (SD) for
continuous variables and frequencies with percentages
for qualitative variables.
Detection of the recalibration effect of the RS
RS analyses were performed on patients with available
scores at both the the then-test and the corresponding
pre-test. The mean differences between the prospective
measure performed at T0 and the retrospective meas-
urement performed at T1 as well as between the
prospective measure performed at T1 and the retro-
spective measurement performed at T2 were calculated
for each HRQOL score. Results were presented accord-
ing to each response category of the anchor’s question in
order to detect the magnitude of the RS effect according
to the observed changes.
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As the MID is defined as the smallest change between
two scores, we were particularly interested in the two
categories “little worse” and “little better” to interpret
the results.
We looked at the direction of the RS effect: a positive
(respectively, negative) value of RS indicates that pa-
tients had overestimated (respectively, underestimated)
their HRQOL level, their functional or symptomatic
level at the previous measurement time.
Then, we were interested in the evolution of the mag-
nitude of the RS effect over time, it means, if the RS
effect had increased or decreased over time in absolute
value.
Finally, the direction of the response shift effect over
time was also analyzed, i.e. if the RS remained positive
or negative at both follow-up time points.
The impact of sample size was indicated by calculation
of the 95% confidence intervals (95%CI).
The p-values calculated by the non-parametric Wil-
coxon paired test were also presented to indicate the
statistical significance of the RS.
The effect size (ES) was calculated to detect the mag-
nitude of the recalibration component of the RS effect
for each category of the anchor. The ES represents the
mean change between the pre-test and the then-test
divided by the standard deviation (SD) of the pre-test
score. We used Cohen’s generally accepted criteria for
interpreting the magnitude of the ES in absolute value:
an ES of at least 0.20 was considered as a small change,
between 0.2 and 0.50 as a moderate change, and greater
than 0.80 as an important change [20].
Observed and adjusted MID
MID were determined by calculating the observed
changes (i.e. without taking into account the RS ef-
fect) and the adjusted changes (i.e. taking into ac-
count the RS effect) given by post-test minus pre-test
and post-test minus then-test respectively. Observed
changes for each score were estimated on patients
with the corresponding score available at both the
post-test and pre-test measurement times. Adjusted
changes for each score were performed on patients
with the corresponding score available for both the
post-test and then-test. In the both cases, the mean
differences were calculated for each HRQOL scores
according to each response category of the anchor’s
question.
The impact of sample size was indicated by calculation
of the 95%CI of the mean difference.
The global range for the observed and adjusted MID
for all dimensions was then reported by questionnaire
and measurement times.
Results of the observed and adjusted MID were fi-
nally compared to the threshold of 5 points MID
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Table 2 The Response shift effect for the QLQ-C30 questionnaire after three and six months for all patients and three main categories of
the anchor
QLQ-C30 After 3 months After 6 months
Between T0 and T1 Between T1 and T2
N RS (SD) 95%CI P-value ES N RS (SD) 95% CI P-value ES
GHS 251 3.82 (17.85) 0.02 0.20 251 −0.03 (21.04) 0.97 0
Little worse 71 3.87 (15.86) (1, 7) 0.24 0.25 51 −8.33 (19.22) (−13, −4) 0.03 −0.42
No change 43 6.78 (15.67) (3, 11) 0.08 0.40 50 8 (19.04) (3, 13) 0.03 0.42
Little better 58 1.29 (17.51) (−3, 5) 0.67 0.08 67 −0.25 (21.61) (−5, 4) 0.80 −0.01
Physical functioning 255 1.54 (12.95) 0.30 0.11 255 −5.2 (12.86) 0 −0.32
Little worse 73 −0.53 (11.11) (−3, 2) 0.49 −0.05 53 −9.56 (10.42) (−12, −7) 0 −0.52
No change 46 1.30 (13.67) (−2, 5) 0.17 0.09 51 −2.29 (8.5) (−4, 0) 0.13 −0.26
Little better 57 3.83 (14.47) (1, 7) 0.45 0.28 69 −3.94 (14.71) (−7, −1) 0.04 −0.25
Role functioning 253 6.06 (21.71) 0 0.32 253 −8.17 (27.07) 0 −0.29
Little worse 73 6.62 (19.98) (3, 11) 0.04 0.46 51 −15.69 (28.95) (−22, −9) 0 −0.52
No change 46 3.26 (16.34) (−1, 7) 0.07 0.19 51 −1.96 (18.45) (−6, 2) 0.67 −0.11
Little better 55 10 (26.57) (4, 16) 0.05 0.45 68 −5.88 (26.67) (−11, 0) 0.24 −0.21
Emotional functioning 254 −7.56 (21.03) 0 −0.29 254 2.20 (22.68) 0.20 0.09
Little worse 72 −9.34 (20.97) (−13, −5) 0 −0.38 52 −5.66 (19.77) (−10, −1) 0.16 −0.24
No change 44 −8.52 (17.14) (−13, −4) 0.03 −0.42 50 8.94 (21.58) (4, 14) 0.04 0.47
Little better 59 −11.11 (23.15) (−16, −6) 0.01 −0.43 69 5.68 (21.83) (1, 10) 0.10 0.23
Cognitive functioning 254 −3.94 (16.85) 0.01 −0.19 254 −3.08 (20.03) 0.04 −0.15
Little worse 73 −5.48 (20.04) (−9, −2) 0.08 −0.26 52 −10.58 (21.9) (−16, −5) 0.02 −0.42
No change 44 −1.52 (10.67) (−4, 1) 0.69 −0.11 50 −2.33 (16.5) (−6, 2) 0.35 −0.16
Little better 57 −5.85 (19.29) (−10, −2) 0.08 −0.27 69 0.97 (18.28) (−3, 5) 0.98 0.05
Social functioning 249 5.09 (19.43) 0 0.28 249 −5.96 (24.47) 0.01 −0.23
Little worse 72 5.32 (19.94) (1, 9) 0.05 0.39 52 −10.90 (25.54) (−17, −5) 0.02 −0.40
No change 42 3.17 (14.37) (−1, 7) 0.08 0.24 49 −4.76 (16.67) (−9, −1) 0.40 −0.22
Little better 59 3.67 (20.55) (−1, 8) 0.59 0.18 68 −1.23 (24.32) (−6, 4) 0.91 −0.05
Financial difficulties 240 −1.11 (15.32) 0.30 −0.08 240 2.50 (16.26) 0.22 0.12
Little worse 69 −1.45 (12.04) (−4, 1) 0.58 −0.14 49 8.16 (24.09) (2, 14) 0.13 0.30
No change 41 −1.63 (7.27) (−4, 0) 0.31 −0.31 47 −0.71 (4.86) (−2, 0) 0.57 −0.15
Little better 58 0.57 (15.91) (−3, 4) 0.86 0.03 66 −1.01 (16.51) (−4, 2) 0.82 −0.05
Fatigue 254 −1.20 (19.42) 0.51 −0.06 254 10.83 (23.93) 0 0.41
Little worse 73 −4.57 (21.36) (−9, 0) 0.31 −0.33 53 19.92 (23.23) (15, 25) 0 0.85
No change 46 −2.17 (15.29) (−6, 2) 0.62 −0.12 51 3.70 (20.08) (−1, 8) 0.32 0.20
Little better 57 −4.58 (21.29) (−9, 0) 0.35 −0.23 68 9.97 (23.76) (5, 15) 0.01 0.44
Nausea and vomiting 255 −1.37 (13.59) 0.26 −0.13 255 3.59 (17.65) 0 0.19
Little worse 74 −0.45 (15.35) (−3, 3) 0.71 −0.05 53 4.09 (14.58) (1, 7) 0.09 0.26
No change 46 0.72 (9.91) (−2, 3) 1 0.04 51 0.98 (10.23) (−1, 3) 0.10 0.10
Little better 57 −5.26 (15.16) (−9, −2) 0.05 −0.87 70 6.67 (25.44) (2, 12) 0.05 29
Pain 260 −3.33 (22.51) 0.14 −0.16 260 5.83 (22.2) 0 0.23
Little worse 75 −4.67 (21.32) (−9, −1) 0.29 −0.24 54 15.43 (26.27) (9, 21) 0 0.56
No change 46 1.45 (18.2) (−3, 6) 0.83 0.09 52 2.24 (13.21) (−1, 5) 0.30 0.18
Little better 57 −7.31 (23.57) (−13, −2) 0.16 −0.35 70 −0.24 (23.14) (−5, 4) 0.80 −0.01
Dyspnea 251 1.20 (15.16) 0.59 0.06 251 3.98 (22.4) 0.03 0.17
Little worse 73 2.28 (15.04) (−1, 5) 0.38 0.11 52 3.85 (27.74) (−3, 10) 0.14 0.17
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which is widely used for the EORTC HRQOL ques-
tionnaires [2].
All analyses were performed using R statistical
software (version 3.2.1) [21].
Results
Patients
Between February 2006 and February 2008, 381 patients
with confirmed or suspicion breast cancer were included
in the four participating centers (Fig. 1). A difference be-
tween centers was observed in terms of questionnaires
completions rate due to logistics problems. Mean age
was 58.4 (SD = 11) years. Three hundred and forty
(89.2%) patients had a confirmed breast cancer. the clin-
ical and socio- demographic characteristics of all pa-
tients were described in Table 1.
Detection of the recalibration component of the
Response shift effect
Tables 2 and 3 present the results of RS effect at T1 and
T2 for the QLQ-C30 and QLQ-BR23 questionnaires
respectively (see Additional file 1: Tables S1 and S2 for
complementary results).
For 18 over 22 dimensions analysed of both question-
naires, an increase of the magnitude of the RS effect was
observed in case of little deterioration over time, i.e.
between T0 and T1 and then between T1 and T2 (i.e.
category “little worse” for the anchor at each follow-up
time point).
To illustrate:
– For the insomnia dimension of the QLQ-C30
questionnaire, the RS effect was equal to 2.42 in
mean at three months reflecting that patients had
overestimated their baseline insomnia level, consid-
ering the retrospective measure at three months as
the reference. The RS effect became more important
after six months by increasing to 10.9 in mean
reflecting an overestimation of the insomnia level at
T1. Thus, the magnitude of the RS effect increased
at six months as compared to three months, with a
positive direction of the RS at both time points.
– Regarding the body image dimension of the QLQ-
BR23 module, the magnitude of the mean RS effect
also increase between each follow-up time point
from 5.04 to 11.17 in absolute value but with an
opposite direction of RS was shown at T1 equal to
5.04 in mean compared with its value after six
months by increasing to −11.17 with underestima-
tion of body image pre-test score at T1.
ES indicate a moderate RS effect in case of deterior-
ation after six months for physical, role, cognitive social
and sexual functioning as well as for pain, appetite loss,
and systemic therapy side effects dimensions (ES > 0.5)
and an important RS effect for fatigue (ES > 0.8). Fur-
thermore, a statistically significance of RS effect has
been indicated (for information only since sample sizes
Table 2 The Response shift effect for the QLQ-C30 questionnaire after three and six months for all patients and three main categories of
the anchor (Continued)
No change 45 0 (12.31) (−3, 3) 0.77 0 51 0.65 (10.52) (−2, 3) 0.79 0.05
Little better 55 0.61 (17.56) (−3, 5) 0.77 0.03 67 3.98 (22.11) (−1, 8) 0.51 0.17
Insomnia 249 6.83 (30.64) 0.01 0.22 249 3.08 (30.41) 0.30 0.10
Little worse 69 2.42 (29.33) (−3, 8) 0.49 0.08 52 10.9 (37.18) (2, 2) 0.07 0.33
No change 46 7.25 (26.21) (1, 14) 0.27 0.25 50 3.33 (25.42) (−3, 9) 0.24 0.18
Little better 55 7.88 (37.93) (−1, 16) 0.11 0.27 67 −1.49 (29.83) (−8, 5) 0.74 −0.05
Appetite loss 249 2.28 (21.05) 0.23 0.11 249 4.69 (22.2) 0.03 0.19
Little worse 73 0.91 (20.77) (−3, 5) 0.55 0.06 53 13.84 (24.84) (8, 20) 0 0.51
No change 46 4.35 (13.35) (1, 8) 0.19 0.22 50 0.67 (15.78) (−3, 4) 0.98 0.03
Little better 54 1.85 (22.82) (−3, 7) 0.79 0.09 68 1.96 (21.46) (−2, 6) 0.74 0.09
Constipation 247 0 (22.61) 0.87 0 247 4.18 (25.89) 0.05 0.16
Little worse 68 −4.90 (18.45) (−9, −1) 0.19 −0.26 48 4.17 (25.38) (−2, 10) 0.29 0.16
No change 42 2.38 (18.61) (−2, 7) 0.42 0.11 48 2.08 (14.43) (−1, 6) 0.43 0.15
Little better 58 0 (27.22) (−6, 6) 0.87 0 70 2.86 (35.32) (−4, 10) 0.71 0.10
Diarrhea 248 2.42 (14.99) 0.09 0.15 248 0.94 (20.28) 0.42 0.06
Little worse 71 3.29 (16.09) (0, 6) 0.28 0.18 48 3.47 (14.16) (0, 7) 0.22 0.23
No change 43 1.55 (12.50) (−2, 5) 0.54 0.13 48 −0.69 (14.57) (−4, 3) 0.98 −0.07
Little better 56 2.98 (17.15) (−1, 7) 0.34 0.16 69 0 (26.81) (−5, 5) 0.86 0
GHS global health status, RS response shift, SD standard deviation, CI confidence interval, ES effect size
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for each test do not allow to produce some results with
a high statistical power) for 12 dimensions of both
QLQ-C30 and QLQ-BR23 questionnaires in case of
deterioration after six months (P-value < 0.05).
A decrease of the magnitude of the RS effect was
observed for 13/22 dimensions analyzed in case of im-
provement betweenT1 and T2 (i.e. category “little better”
for the anchor at T1 and at T2). For example:
– A decrease of RS effect with underestimation of pain
level at T0 and T1 from −7.31 after three months to
−0.24 after six months for;
– A decrease of RS effect from 9.98 with
overestimation of baseline body image level to −2.74
with underestimation of body image pre-test score
at T1.
For all dimensions for which a decrease of RS effect
was observed between T1 and T2 in case of improve-
ment of HRQOL level, the ES indicated an insignificant
RS (ES ≤ 0.2) or a small change (0.2 < ES ≤ 0.5). In
addition, results were not statistically significant (p-
values of the Wilcoxon test ≥ 0.05).
In case of deterioration, the same direction of RS
between T1 and T2 was observed for 11/22
dimensions of both QLQ-C30 and QLQ-BR23
questionnaires. In case of improvement, the direction
of the RS effect remained the same for only 3/22
Table 3 The Response shift effect for the QLQ-BR23 questionnaire after three and six months for all patients and three main categories
of the anchor
After 3 months After 6 months
Between T0 and T1 Between T1 and T2
QLQ-BR23 N RS (SD) 95%CI P-value ES N RS (SD) 95%CI P-value ES
Body image 232 6.50 (20.73) 0.01 0.37 232 −7.18 (22.33) 0.01 −0.23
Little worse 70 5.04 (17.89) (1, 9) 0.11 0.32 47 −11.17 (21.1) (−16, −6) 0.03 −0.37
No change 41 3.25 (14.54) (−1, 7) 0.11 0.20 46 −3.62 (12.25) (−7, −1) 0.28 −0.19
Little better 49 9.98 (23) (4, 15) 0.11 0.62 65 −2.74 (24.7) (−8, 2) 0.63 −0.09
Sexual functioning 198 0.76 (15.06) 0.77 0.03 198 4.29 (18.88) 0.10 0.19
Little worse 56 0.60 (15.56) (−3, 4) 0.90 0.02 38 10.96 (19.86) (6, 16) 0.07 0.52
No change 34 1.96 (15.77) (−3, 7) 0.73 0.08 41 0.41 (18.44) (−4, 5) 0.90 0.01
Little better 43 −1.94 (12.71) (−5, 1) 0.77 −0.08 56 0.89 (16.02) (−3, 4) 0.88 0.05
Sexual enjoyment 74 −4.05 (20.74) 0.26 −0.16 74 3.15 (23.49) 0.21 0.13
Little worse 23 −2.90 (24.44) (−12, 6) 0.59 −0.16 16 2.08 (30.96) (−11, 16) 0.55 0.10
No change 16 −6.25 (13.44) (−12, 0) 0.51 −0.23 23 1.45 (25.58) (−8, 11) 0.69 0.06
Little better 11 −3.03 (23.35) (−16, 10) 0.80 −0.10 16 2.08 (14.75) (−4, 9) 0.83 0.08
Future perspectives 236 −7.91 (30.3) 0.01 −0.27 236 1.27 (30.77) 0.64 0.04
Little worse 68 −16.18 (27.31) (−22, −11) 0 −0.56 48 −4.17 (31.98) (−12, 4) 0.49 −0.13
No change 43 −13.18 (29.22) (−21, −6) 0.04 −0.47 49 4.76 (34.69) (−4, 13) 0.47 0.18
Little better 48 −6.94 (32.95) (−15, 1) 0.22 −0.28 63 7.41 (25.71) (2, 13) 0.18 0.23
Systemic therapy side effects 252 0.42 (12.32) 0.73 0.03 252 8.16 (16.76) 0 0.42
Little worse 72 0.96 (12.49) (−1, 3) 0.78 0.07 53 13.76 (19.15) (9, 18) 0 0.73
No change 45 −0.56 (8.12) (−3, 1) 0.90 −0.04 52 2.22 (8.64) (0, 4) 0.53 0.19
Little better 54 0 (12.64) (−3, 3) 0.47 0 65 8.13 (19.39) (4, 12) 0 0.45
Breast symptoms 212 −2.59 (19.13) 0.69 −0.18 212 8.54 (20.19) 0 0.35
Little worse 57 4 (17.94) (0, 8) 0.09 0.24 47 10.76 (19.94) (6, 16) 0.01 0.4
No change 36 −0.62 (11.35) (−4, 3) 0.68 −0.07 42 7.34 (16.22) (3, 12) 0.02 0.47
Little better 53 −9.49 (21.49) (−14, −5) 0.12 −0.76 59 5.84 (14.8) (3, 9) 0.17 0.23
Arm symptoms 235 −1.94 (16.33) 0.50 −0.14 235 3.81 (19.17) 0.02 0.21
Little worse 67 0.66 (18) (−3, 4) 0.55 0.05 48 10.19 (20.06) (5, 15) 0 0.47
No change 41 1.36 (7.93) (−1, 3) 0.31 0.16 50 4 (10.88) (1, 7) 0.01 0.36
Little better 55 −3.13 (18.07) (−7, 1) 0.45 −0.18 64 0 (17.51) (−4, 4) 0.71 0
RS response shift, SD standard deviation, CI confidence interval, ES effect size
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Table 4 Observed and adjusted changes of the QLQ–C30 questionnaire after three and six months
QLQ-C30 After 3 months After 6 months
Between T0 and T1 Between T1 and T2
Observed changes Adjusted changes Observed changes Adjusted changes
(post-test - pre-test) (post-test - then-test) (post-test - pre-test) (post-test - then-test)
N Mean (SD) 95% CI Mean (SD) 95% CI N Mean (SD) 95% CI Mean (SD) 95% CI
GHS 251 251
Little worse 71 −16.31 (16.99) (−20, −13) −12.44 (16.78) (−16, −9) 51 0.49 (15.4) (−3, 4) −7.84 (15.22) (−11, −4)
No change 43 −2.13 (16.17) (−6, 2) 4.65 (17.85) (0, 9) 50 −1 (16.12) (−5, 3) 7 (14.71) (4, 10)
Little better 58 0.29 (18.4) (−4, 4) 1.58 (14.93) (−2, 5) 67 7.21 (17.22) (4, 11) 6.97 (16.70) (4, 10)
Physical functioning 255 255
Little worse 73 −11.76 (10.99) (−14, −10) −12.28 (12.71) (−15, −10) 53 0.38 (11.43) (−2, 3) −9.18 (12.83) (−12, −6)
No change 46 −3.99 (10.17) (−7, −1) -2.68 (12.76) (−6, 0) 51 0.72 (6.97) (−1, 2) −1.57 (6.34) (−3, 0)
Little better 57 −4.53 (12.89) (−7, −2) -0.70 (11.86) (−3, 2) 69 0.85 (13.02) (−2, 3) −3.09 (14.03) (−6, 0)
Role functioning 253 253
Little worse 73 −25.57 (21.71) (−30, −21) -18.95 (23.78) (−24, −14) 51 −1.96 (29.18) (−9, 5) −17.65 (29.14) (−24, −11)
No change 46 −2.90 (19.66) (−8, 2) 0.36 (21.80) (−5, 6) 51 3.92 (15.49) (0, 8) 1.96 (19.05) (−3, 6)
Little better 55 −9.09 (20.74) (−14, −4) 0.91 (24.72) (−5, 6) 68 5.88 (21.89) (1, 1) 0 (23.92) (−5,5)
Emotional functioning 254 254
Little worse 72 3.05 (24.09) (−2, 8) -6.29 (22.02) (−11, −2) 52 −0.53 (20.19) (−5, 4) −6.20 (16.43) (−10, −2)
No change 44 19.44 (18.31) (15, 24) 10.92 (18.26) (6, 16) 50 −0.78 (15.55) (−4, 3) 8.17 (21.26) (3, 13)
Little better 59 15.07 (26.33) (9, 21) 3.95 (19.51) (0, 8) 69 1.53 (20.05) (−2, 6) 7.21 (19.13) (3, 11)
Cognitive functioning 254 254
Little worse 73 −5.48 (19.46) (−9, −2) -10.96 (18.26) (−15, −7) 52 0.96 (17.9) (−3, 5) −9.62 (19.06) (−14, −5)
No change 44 0.76 (13.43) (−3, 4) -0.76 (12.43) (−4, 2) 50 2.67 (12.31) (0, 6) 0.33 (15.97) (−3, 4)
Little better 57 5.26 (21.4) (1, 1) -0.58 (17.24) (−4, 3) 69 3.62 (13.37) (1, 6) 4.59 (17.82) (1, 8)
Social functioning 249 249
Little worse 72 −20.37 (21.34) (−25, −16) -15.05 (14.84) (−18, −12) 52 0.64 (24.47) (−5, 6) −10.26 (20.39) (−15, −6)
No change 42 −3.97 (21.08) (−9, 2) -0.79 (17.25) (−5, 4) 49 4.42 (19.18) (0, 9) −0.34 (12.50) (−3, 3)
Little better 59 −6.78 (19.6) (−11, −3) -3.11 (18.95) (−7, 1) 68 3.43 (20.68) (−1, 8) 2.21 (21.34) (−2, 7)
Fatigue 254 254
Little worse 73 27.32 (21.87) (23, 32) 22.75 (22.38) (18, 27) 53 0.21 (16.34) (−4, 4) 20.13 (24.17) (15, 26)
No change 46 7.73 (18.42) (3, 12) 5.56 (19.42) (1, 10) 51 −1.53 (19.5) (−6, 3) 2.18 (19.75) (−2, 7)
Little better 57 7.89 (19.47) (4, 12) 3.31 (17.97) (−1, 7) 68 −7.68 (18.24) (−11, −4) 2.29 (22.92) (−2, 7)
Nausea and vomiting 255 255
Little worse 74 8.78 (19.35) (5, 13) 8.33 (15.67) (5, 11) 53 −3.14 (21.7) (−8, 2) 0.94 (17.73) (−3, 5)
No change 46 −0.72 (12.65) (−4, 2) 0 (8.61) (−2, 2) 51 −2.29 (10.01) (−5, 0) −1.31 (12.40) (−4, 2)
Little better 57 9.06 (21.38) (4, 14) 3.80 (17.82) (0, 8) 70 −6.67 (23.98) (−11, −2) 0 (13.31) (−3, 3)
Pain 260 260
Little worse 75 13.78 (24.87) (9, 19) 9.11 (23.14) (5, 14) 54 1.85 (22.35) (−3, 7) 17.28 (25.89) (11, 23)
No change 46 3.99 (14.57) (0, 8) 5.43 (17.23) (1, 10) 52 3.21 (14.02) (0, 6) 5.45 (17.06) (1, 9)
Little better 57 9.94 (20.62) (5, 15) 2.63 (21.08) (−2, 7) 70 2.14 (20.05) (−2, 6) 1.90 (22.97) (−3, 6)
Dyspnea 251 251
Little worse 73 8.68 (24.86) (4, 14) 10.96 (23.61) (6, 16) 52 3.85 (26.94) (−2, 10) 7.69 (18.22) (3, 12)
No change 45 0.74 (19.45) (−4, 6) 0.74 (18.10) (−4, 5) 51 −0.65 (12.45) (−4, 2) 0 (11.55) (−3, 3)
Little better 55 1.21 (19.21) (−3, 6) 1.82 (16.25) (−2, 5) 67 3.48 (22.57) (−1, 8) 7.46 (23.08) (3, 12)
Insomnia 249 249
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dimensions (namely, pain, dyspnea and appetite loss
dimensions).
Observed and adjusted MID
Tables 4 and 5 represent the results of the observed and
adjusted MID at 3 and 6 months for the QLQ-C30 and
QLQ-BR23 respectively (see Additional file 1: Tables S3
and S4 for complementary results).
Based on the scales that have at the same time an
increase of the RS effect in case of deterioration and a
decrease of the RS effect in case of improvement (GHS,
role, cognitive, social and sexual functioning, pain,
insomnia, diarrhea, body image, breast and arm symp-
toms), the minimal and maximal MID for observed and
adjusted MID were calculated in case of deterioration
and improvement of HRQOL after three and six months
(Table 6). The diarrhea scale was excluded from the
analysis because it will disrupt the results; due to a num-
ber of scores containing zero values. The financial diffi-
culties and appetite loss dimensions were also added
since a remarkable increase was observed when deterior-
ating and a relatively low increase was highlighted when
improving.
A comparison of the observed and adjusted changes in
case of a small deterioration (category “little worse”) to a
threshold of 5 points for both the QLQ-C30 and QLQ-
BR23 questionnaires after three and six months was
presented in Table 7.
The variations of the RS effect between 3 and 6 months
were represented on Figs. 2 and 3 for several HRQOL
dimensions. For example, the Fig. 2 illustrates an
increase of the RS effect in mean in case of a small
deterioration and a decrease in case of a small improve-
ment for the most dimensions of the QLQ-C30. Some
consistent results for the most dimensions of the QLQ-
BR23 questionnaire were also detected and illustrated in
Fig. 3.
Discussion
The objective of this study was to explore the impact of
the occurrence of the response shift effect on the
determination of the MID over time in breast cancer
patients using both the QLQ-C30 and QLQ-BR23
questionnaires.
Both an increase of the RS effect in case of deterior-
ation and a decrease of the RS effect in case of improve-
ment was observed for 7/15 dimensions of the QLQ-
C30 questionnaire (global health status (GHS), role, cog-
nitive and social functioning, pain, insomnia, diarrhea)
and 4/7 dimensions for the QLQ-BR23 questionnaire
(body image, sexual function, breast and arm symp-
toms). This indicates the differential occurrence of the
RS effect according to the change in patient’s HRQOL
level over time (i.e. deterioration or improvement of
HRQOL).
For 13/15 dimensions of the QLQ-C30 questionnaire
(except the emotional functioning and the constipation
Table 4 Observed and adjusted changes of the QLQ–C30 questionnaire after three and six months (Continued)
Little worse 69 5.80 (35.22) (−1, 13) 8.21 (28.24) (3, 14) 52 4.49 (30.98) (−3, 12) 15.38 (24.22) (10, 21)
No change 46 −10.14 (35.04) (−19, −1) −2.90 (25.17) (−9, 3) 50 −1.33 (21.25) (−6, 4) 2 (28.89) (−5, 9)
Little better 55 −7.27 (34.95) (−15, 1) 0.61 (25.25) (−5, 6) 67 1 (30.13) (−5, 7) −0.50 (22.09) (−5, 4)
Appetite loss 249 249
Little worse 73 10.05 (28.16) (5, 16) 10.96 (27.25) (6, 16) 53 −10.06 (25.8) (−16, −4) 3.77 (20.32) (−1, 8)
No change 46 −2.90 (20.88) (−8, 2) 1.45 (17.15) (−3, 6) 50 −2.67 (9.13) (−5, −1) −2 (12.44) (−5, 1)
Little better 54 1.85 (22.82) (−3, 7) 3.70 (15.41) (0, 7) 68 −2.45 (20.21) (−7, 2) −0.49 (14.67) (−3, 2)
Constipation 247 247
Little worse 68 15.20 (30.16) (9, 21) 10.29 (27.77) (5, 16) 48 −1.39 (24.75) (−7, 5) 2.78 (21.56) (−2, 8)
No change 42 0 (19.48) (−5, 5) 2.38 (18.61) (−2, 7) 48 −3.47 (12.38) (−6, 0) −1.39 (9.62) (−4, 1)
Little better 58 0 (26.49) (−6, 6) 0 (16.52) (−4, 4) 70 −2.86 (30.95) (−9, 3) 0 (26.62) (−5, 5)
Diarrhea 248 248
Little worse 71 0 (21.08) (−4, 4) 3.29 (18.07) (0, 6) 48 0.69 (14.57) (−3, 4) 4.17 (13.09) (1, 7)
No change 43 −2.33 (15.25) (−6, 2) -0.78 (11.47) (−4, 2) 48 −1.39 (9.62) (−4, 1) −2.08 (10.67) (−5, 0)
Little better 56 −0.6 (21.55) (−5, 4) 2.38 (20.94) (−2, 7) 69 −1.93 (17.97) (−6, 2) −1.93 (20.52) (−6, 2)
Financial difficulties 240 240
Little worse 69 9.66 (22.94) (5, 14) 8.21 (22.44) (4, 13) 49 −3.40 (20.69) (−8, 2) 4.76 (21.52) (0, 1)
No change 41 4.07 (13.32) (1, 8) 2.44 (8.79) (0, 5) 47 0 (0) (NA) −0.71 (4.86) (−2, 0)
Little better 58 1.15 (22.48) (−4, 6) 1.72 (15.82) (−2, 5) 66 1.52 (9.12) (0, 3) 0.51 (16) (−3, 4)
GHS global health status, Observed changes Post-test – Pre-test; adjusted changes: Post-test – Then-test, SD standard deviation, CI confidence interval
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Table 5 Observed and adjusted changes of the QLQ–BR23 questionnaire after three and six months
After 3 months After 6 months
Between T0 and T1 Between T1 and T2
QLQ-BR23 Observed changes Adjusted changes Observed changes Adjusted changes
(post-test - pre-test) (post-test - then-test) (post-test - pre-test) (post-test - then-test)
N Mean (SD) 95% CI Mean (SD) 95% CI N Mean (SD) 95% CI Mean (SD) 95% CI
Body image 232 232
Little worse 70 −20.44 (27.41) (−26, −15) −15.40 (25.02) (−20, −10) 47 0.41 (16.58) (−4, 4) −10.76 (22.82) (−16, −5)
No change 41 −7.32 (15.16) (−11, −3) −4.07 (15.60) (−8, 0) 46 2.72 (10.1) (0, 5) −0.91 (12.82) (−4, 2)
Little better 49 −14.91 (24.41) (−21, −9) −4.93 (18.31) (−9, −1) 65 1.28 (22.93) (−3, 6) −1.45 (20.88) (−6, 3)
Sexual functioning 198 198
Little worse 56 6.85 (20.79) (2, 11) 7.44 (21.06) (3, 12) 56 −0.44 (12.55) (−4, 3) 10.53 (17.93) (6, 15)
No change 34 3.92 (22.87) (−3, 11) 5.88 (22.80) (−1, 13) 34 2.03 (16.33) (−2, 6) 2.44 (16.48) (−2, 7)
Little better 43 1.94 (15.94) (−2, 6) 0 (10.91) (−3, 3) 43 −0.89 (18.1) (−5, 3) 0 (17.70) (−4, 4)
Sexual enjoyment 74 74
Little worse 23 14.49 (19.66) (7, 22) 11.59 (19.09) (5, 18) 23 12.50 (29.5) (0, 25) 14.58 (20.97) (5, 24)
No change 16 10.42 (33.82) (−4, 25) 4.17 (29.50) (−9, 17) 16 1.45 (21.27) (−6, 9) 2.90 (28.27) (−7, 13)
Little better 11 12.12 (22.47) (0, 24) 9.09 (21.56) (−3, 21) 11 −2.08 (22.67) (−12, 8) 0 (21.08) (−9, 9)
Future perspectives 236 236
Little worse 68 7.35 (32.5) (1, 14) −8.82 (30.81) (−15, −3) 68 3.47 (30.16) (−4, 11) −0.69 (24.30) (−7, 5)
No change 43 20.93 (32.55) (13, 29) 7.75 (26.06) (1, 14) 43 0 (23.57) (−6, 6) 4.76 (30.43) (−3, 12)
Little better 48 10.42 (30.1) (3, 18) 3.47 (24.06) (−2, 9) 48 1.06 (25.38) (−4, 6) 8.47 (23.92) (3, 13)
Systemic therapy side effects 252 252
Little worse 72 18.83 (21.51) (15, 23) 19.79 (18.60) (16, 23) 72 −3.49 (18.26) (−8, 1) 10.27 (18.90) (6, 15)
No change 45 4.41 (15.02) (1, 8) 3.84 (14.03) (0, 7) 45 0.23 (10.2) (−2, 3) 2.45 (7.89) (1, 4)
Little better 54 6.02 (13.64) (3, 9) 6.02 (12.35) (3, 9) 54 −4.19 (15.12) (−7, −1) 3.94 (19.39) (0, 8)
Breast symptoms 212 212
Little worse 57 14.08 (27.69) (8, 2) 18.08 (22.21) (13, 23) 57 −4.31 (16.81) (−8, 0) 6.44 (18.26) (2, 11)
No change 36 10.34 (20.43) (5, 16) 9.72 (21.59) (4, 16) 36 −3.57 (13.35) (−7, 0) 3.77 (14.28) (0, 7)
Little better 53 16.61 (21.1) (12, 21) 7.13 (18.87) (3, 11) 53 −2.21 (20.17) (−7, 2) 3.63 (20.65) (−1, 8)
Arm symptoms 235 235
Little worse 67 7.88 (17.6) (4, 11) 8.54 (19.28) (5, 12) 67 0.58 (18.27) (−4, 5) 10.76 (19.53) (6, 15)
No change 41 3.39 (13.54) (0, 7) 4.74 (14.14) (1, 8) 41 1.89 (13.82) (−1, 5) 5.89 (14.65) (2, 9)
Little better 55 4.55 (17.51) (1, 8) 1.41 (13.83) (−2, 5) 55 0.69 (13.98) (−2, 4) 0.69 (16.93) (−3, 4)
Observed changes Post-test – Pre-test; adjusted changes: Post-test – Then-test
SD standard deviation, CI confidence interval
Table 6 MID in case of deterioration and improvement of HRQOL for both QLQ-C30 and QLQ-BR23 questionnaires after three and
six months
Deterioration of HRQOL Improvement of HRQOL
Observed changes Adjusted changes Observed changes Adjusted changes
QLQ-BR23 QLQ - C30
After 3 months 5–26 8–19 0.3–10 0.6–4
After 6 months 0.5–10 4–18 0.8–7 0–7
After 3 months 7–20 7–18 2–15 0–7
After 6 months 0.4–4 6–11 0.7–2 0–4
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dimensions) and 5/7 dimensions of the QLQ-BR23 ques-
tionnaire (except the sexual enjoyment and the future
perspectives dimensions), an increase of the RS effect
was observed in case of deterioration between T1 and
T2. The RS effect becomes increasingly important over
time specifically for the anchor category « little worse ».
This indicates that the RS must be considered when de-
termining the MID for deterioration.
For 8/15 dimensions of QLQ-C30 questionnaire (GHS,
role, emotional, social and cognitive functioning, pain,
diarrhea and insomnia dimensions) and 5/7 dimensions
of the QLQ-BR23 questionnaire (except the sexual
enjoyment and the future perspectives dimensions), a
decrease of the RS effect was observed in case of
improvement with corresponding ES values close to zero
and p-values ≥ 0.05. These values mean that the impact
of the RS effect became negligible on the determination
of the MID in case of improvement after six months.
Regarding the QLQ-C30 questionnaire, the ob-
served MID in case of deterioration after three
months was between 5 and 26 points: a mean differ-
ence of 5 points was sufficient to conclude that the
difference was clinically significant at T1. After tak-
ing into account the RS effect, the minimal differ-
ence considered as important for patients increased
to 8 points. Furthermore, the adjusted MID became
between 8 and 19 points and thus more restricted
than it was for the observed changes (without taking
into account the RS effect). However, at T2, the ob-
served MID was between 0.5 and 10 then became
between 4 and 18 for the adjusted MID. Thus, if we
did not have taken into account the occurrence of
the RS effect, we can wrongly conclude that a deteri-
oration of 0.5 point is considered as the MID for the
patients which seems to be very low. Whereas, after
taking into account the RS effect, the mean differ-
ence became between 4 and 18 points which seems
to be more relevant than the previous interval.
Comparing the results of adjusted MID in case of
deterioration at T1 and T2, we find that the MID was
between 8 and 19 points at T1 then became between 4
and 18 points at T2, which means that a smaller change
of HRQOL can be considered as clinically significant to
the patients. In other words, a difference of 4 points out
of 100 was not enough to say that this difference was
significant after three months; but the same difference
became significant to the patient after 6 months. In
addition, consistent results have been found for the
QLQ-BR23 questionnaire in case of deterioration
concerning the observed and the adjusted MID.
Regarding HRQOL improvement, no impact of the RS
on the determination of the MID was observed. In
contrast, the RS effect seemed to highly impact the MID
for deterioration. To illustrate, the minimal of observed
MID was smaller than one point in case of deterioration
for QLQ-C30 (MID: 0.5–10) and QLQ-BR23 (MID: 0.4–
4) after six months, the minimal of each MID was equal
to 4 points for the QLQ-C30 and to 6 points for QLQ-
BR23 after taking into account the RS effect. Thus, with-
out taking into account the occurrence of the RS effect,
we can wrongly conclude that a difference of less than 1
point is clinically significant to the patients.
For patients who have an improvement in their
HRQOL, the minimal of observed and adjusted MID
Table 7 MID for QLQ-C30 and QLQ-BR23 questionnaires after 3
and 6 months compared to a threshold of 5 points












16 12a 0.5 8a
Physical
functioning
12 12a 0.4 9a
Role
functioning
26 19a 2 18a
Cognitive
functioning
5 11a 1 10a
Social
functioning
20 15a 1 10a
Emotional
functioning
3.5 6a 0.5 6a
Fatigue 27 23a 0.2 20a
Pain 14 9a 2 17a
Dyspnea 9 11a 4 8a
Insomnia 6 8a 4 15a
Financial
difficulties
10 8a 3 5a
Appetite loss 10 11a 10 4
Constipation 15 10a 1 3
Nausea and
vomiting
9 8a 3 1
QLQ-BR23
Body image 20 15a 0.4 11a
Sexual
functioning
7 7a 0.4 11a
Systemic therapy
side effects
19 20a 3 10a
Breast symptoms 14 18a 4 6a
Arm symptoms 8 9a 0.6 11a
Sexual
enjoyment
14 12a 13 15a
Future
perspectives
7 9a 3 0.7
a indicates that the MID stayed or became greater than 5 points when the
response shift effect was taken into account
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Fig. 1 Flowchart with number of questionnaires collected at each measurement time
Fig. 2 Bar charts representing the change of RS effect in the both cases: deterioration (little worse) and improvement (little better) for some
dimensions of QLQ-C30 questionnaire between three and six months
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found for the two questionnaires after three and six
months is close to zero and they all stayed close to zero
after taking into account the RS effect, except for the ob-
served MID after three months for the QLQ-BR23 ques-
tionnaire which was equal to 2 points. We can conclude
that a very small improvement over time can be consid-
ered as important for the patient.
For thirteen over the 15 scales of the QLQ-C30 ques-
tionnaire and all scales of the QLQ-BR23, the observed
and adjusted MID was greater than 5 points after three
months. Whereas, after six months, 11/15 scales of the
QLQ-C30 and 5/7 scales of the QLQ-BR23 had an ob-
served MID smaller than 5 points and became greater
than 5 points after taking into account the RS effect.
Thus, the RS effect seems to have an important impact
on the determination of the MID and notably after six
months.
Our study confirms the earlier results released by
Kvam and al. between two measurement times which
showed that the RS has an important impact on the
results in case of deterioration and was unimportant in
case of improvement [13]. However, this previous study
was limited to two measurement times.
Three measurement times were considered in our
study allowing us to evaluate the change of RS effect
and to detect specifically the dimensions for which an
increase or a decrease of the RS effect was observed over
time. Moreover, using three measurement times allowed
us to compare the MID at three and six months and to
conclude the importance of taking into account the RS
effect in order to obtain a reduced interval of MID and a
MID significant after six months comparing with a
threshold of five points.
Another strength of our study was the consideration
of all dimensions of both QLQ-C30 and QLQ-BR23
breast cancer module. The study of Kvam and al. was on
patients with multiple myeloma and the QLQ-MY20
multiple myeloma module [22] was not yet validated at
the time of the conception of this study, which justifies
the limitation to the QLQ-C30.
Twenty two dimensions have been analysed in our
study that provides to collect a lot of information on di-
mension impacted by the RS effect and trends over time.
A limitation of our study is the use of the then-test
method to assess the occurrence of the RS effect. This
method required to be planned at the time of the con-
ception of the study and may be subject to a recall bias.
Moreover, it focused on the recalibration component to
study the impact of the RS, thus we recommend more
researches in order to determine the impact of the other
components of the RS effect (reprioritization and recon-
ceptualization) on the determination of the MID. The
structural equation modeling may be preferable to the
then-test method to detect all the three components of
the RS in a HRQOL analysis. However, the Oort proced-
ure based on the structural equation modelling to detect
the RS effect was developed and mainly applied the SF-
36 questionnaire [11, 23]. Some researches are still on-
going to adapt this procedure to the EORTC question-
naires [24].
Using item response theory (IRT) may be very import-
ant for the future researches to assess the components
of RS and its impact on the determination of the MID
[19].
Although the use of three measurement times was
useful in this study, but there is a recall bias may affect
the answers of patients over time. In addition, using just
the anchor based approach to compute MID may bias
the finding as the standard practice is the combination
with both anchor and distribution based methods. The
limited number of patients per anchor category is con-
sidered also as a limitation of our study. Hence, further
studies are needed to study the RS trends with a quite
large number of patients per anchor-item category.
The heterogeneity of our data is considered also as a
limitation of this study.
Fig. 3 Bar charts representing the change of RS effect in the both cases: deterioration (little worse) and improvement (little better) for some
dimensions of QLQ-BR23 questionnaire between three and six months
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The MID allows planning studies in order to deter-
mine both the required sample size and the statistical
power. The MID also has a direct impact on the time to
HRQOL score deterioration approach for longitudinal
analysis [25, 26].
Conclusion
Our work has extended the research for the first time to
investigate the RS effect on the determination of the
MID between three measurement times. This investiga-
tion permitted to detect the important role of the RS ef-
fect on the determination and the significance of the
MID in the most scales of two questionnaires six
months after the breast cancer diagnosis. Finally, we rec-
ommend further researches to confirm, support or re-
view our findings and develop novel methods in order to
progress in this field.
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